Author Archive: David Thomas, CFA

David Thomas, CFA

David is currently Senior Director of Industry Research and Analysis at BIO in Washington, DC. In this role, he is responsible for financial statistics and analysis of the biotechnology sector and contributes to BIO’s policy activities as well as programming for BIO’s investor conferences. Prior to joining BIO, he was a research scientist at the J. Craig Venter Institute working on the “synthetic cell” team led by Nobel Laureate Hamilton Smith. Before his role in synthetic biology, David worked as a scientist in drug discovery at Amgen, Millennium, and Novartis. His scientific expertise is in protein engineering, enzymology, and synthetic biology. David has earned the Chartered Financial Analyst (CFA) designation and holds a master’s degree in biochemistry.

Latest Posts

2015 FDA Approvals: Highest Levels in Over a Decade

btn-dave-thomas

2015 was a blockbuster year for FDA approvals of novel new medicines, many of them for serious and life-threatening conditions. As Dr. John Jenkins of the FDA’s Center for Drug Evaluation and Research (CDER) notes in a recent blog post, “During this past year, we approved many new drugs to treat various forms of cancer, including four to treat multiple myeloma, and others to treat lung, skin, breast, brain, colorectal, and other cancers. We also Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

Haves and Have Nots in Biotech Venture Capital

US_VC_Funding_2009_2014

Recent data from the BIO Industry Analysis team tells a story of “haves and have-nots” in US biopharma venture capital. Three key findings were discussed Wednesday at the 14th Annual BIO Investor Forum. The first finding from the recent study is that funding of therapeutic companies is strong for late rounds (Series B and above), but weak for Series A. Although total levels of venture funding have been climbing recently, the majority of the increase is from late rounds. Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , ,

State of the Industry for Emerging Therapeutic Companies

Emerging Therapeutic Company Investment and Deal Trends

Emerging therapeutic companies are at their strongest point in a decade. In our new report on investment and deal trends, the BIO Industry Analysis team shows how this segment within the biotech industry has been faring over the last 10 years. The annual aggregate totals show that for almost every funding or deal activity analyzed, 2014 was the peak year of the last decade. A strong public market, a revitalized private funding environment, and a Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Ten Years of Therapeutic Venture Capital

vc-blog

What therapeutic areas have received the most funding in private drug companies over the last decade? How much of this has been for new drugs vs drug delivery? How much into biologics vs small molecules? This week, we released a first-of-its-kind, comprehensive report on venture capital trends covering 2004-2013. To investigate investor trends in specific therapeutic areas and level of innovation, we analyzed data from four venture capital databases to create the broadest, most comprehensive Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

Therapeutic Licensing and M&A Deals

science lab technician

Licensing deals for therapeutic candidates in 2013 dropped to the lowest volume in at least eight years for deals with disclosed values totaling over $10M. Total upfront payments to biotechs were also at an eight year low, with only $1.9B paid to biotechs in 2013. This is a 50 percent drop from peak levels. However, there is a silver lining in the data: Preclinical deal volume saw a slight increase in 2013, and has not Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,